[Natural History and Treatment Indications of Chronic Hepatitis B]

Area of Science:

• Hepatology
• Virology
• Internal Medicine

Background:

• Hepatitis B virus (HBV) is a primary cause of liver cirrhosis and hepatocellular carcinoma in Korea.
• Current antiviral therapies can manage, but not eliminate, HBV infection.
• Individualized risk-benefit assessment is crucial for antiviral treatment decisions.

Purpose of the Study:

• To outline the strategic considerations for antiviral therapy in chronic HBV infection.
• To emphasize the importance of understanding HBV natural history for treatment decisions.
• To define patient populations who benefit most from antiviral interventions.

Main Methods:

• Review of current clinical guidelines and natural history data for chronic HBV infection.
• Analysis of treatment recommendations based on HBV infection phases (immune-tolerant, immune-active, immune-inactive).
• Consideration of specific patient groups, including those with liver cirrhosis and undergoing immunosuppressive therapy.

Main Results:

• Antiviral therapy is generally not recommended for immune-tolerant or immune-inactive phases, barring special circumstances like immunosuppression.
• Patients in the immune-active phase of chronic HBV infection are candidates for antiviral therapy.
• Treatment should be considered for cirrhotic patients with detectable HBV DNA, irrespective of ALT levels.

Conclusions:

• Antiviral therapy for chronic HBV infection focuses on preventing disease progression and reducing mortality.
• Tailoring treatment based on the phase of infection and clinical status (e.g., cirrhosis) is essential.
• Informed decision-making requires a thorough understanding of HBV natural history and individual patient factors.